Daré Bioscience closes Regulation A unit offering
Daré Bioscience, Inc. completed multiple closings of its ongoing Regulation A unit offering.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Daré Bioscience, Inc. completed multiple closings of its ongoing Regulation A unit offering. The company issued 195,010 Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants to purchase common stock.
The completed closings on May 1, 4, 5 and 6, 2026 resulted in 195,010 shares of Series A Preferred Stock and Investor Warrants to purchase up to 390,020 shares of common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026.
8-K Event Classification
Item 3.02 — Unregistered Sales of Equity Securities
1 item
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Key Figures
Maximum Regulation A units offered: 4,854,000 units
Investor Unit price: $5.00 per unit
Investor Units issued: 195,010 units
+4 more
7 metrics
Maximum Regulation A units offered
4,854,000 units
Regulation A offering capacity
Investor Unit price
$5.00 per unit
Offering price for each Investor Unit
Investor Units issued
195,010 units
Units sold in completed closings
Series A Preferred shares issued
195,010 shares
Shares of Series A Convertible Preferred Stock issued
Common shares underlying warrants
390,020 shares
Maximum common shares purchasable via Investor Warrants
Form 1-A file number
024-12688
Offering statement supporting Regulation A offering
SEC qualification date
April 1, 2026
Most recent qualification of Form 1-A
Key Terms
Regulation A offering, Series A Convertible Preferred Stock, Investor Warrants, offering statement on Form 1-A, +1 more
5 terms
Regulation A offering regulatory
"completed closings of its previously announced Regulation A offering of up to 4,854,000 units"
A Regulation A offering is a way for smaller companies to sell shares to the public without going through a full, traditional stock market listing. Think of it as a scaled-down public sale that gives everyday investors earlier access to private companies while generally requiring less paperwork and oversight than a full IPO—so it can offer growth opportunities but also carries higher risk and potentially less disclosure than fully regulated public stocks.
Series A Convertible Preferred Stock financial
"each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”)"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
Investor Warrants financial
"and two warrants, each to purchase one share of our common stock (“Investor Warrants”)"
Investor warrants are tradable rights that let the holder buy a company’s stock at a fixed price for a limited time. They matter because they can amplify returns if the share price rises above that fixed price, but they also can dilute existing shareholders if exercised; think of a warrant as a coupon that lets you purchase shares later at today’s price, creating potential upside for the holder and a future change in share count for investors.
offering statement on Form 1-A regulatory
"pursuant to our offering statement on Form 1-A (File No. 024-12688), as amended"
offering circular supplement regulatory
"the offering circular dated January 6, 2026, and the offering circular supplement dated March 26, 2026"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Daré Bioscience (DARE) announce in its latest 8-K?
Daré Bioscience reported completing closings of its Regulation A offering, issuing 195,010 Investor Units. Each unit includes one share of Series A Convertible Preferred Stock and two Investor Warrants, advancing its previously qualified capital-raising program under an SEC-qualified Form 1-A offering statement.
How many units did Daré Bioscience (DARE) issue and at what price?
Daré Bioscience issued 195,010 Investor Units at an offering price of $5.00 per unit. Each unit consists of one share of Series A Convertible Preferred Stock and two Investor Warrants, providing potential future access to up to two common shares per unit through warrant exercise.
What securities are included in Daré Bioscience (DARE) Investor Units?
Each Daré Bioscience Investor Unit contains one share of Series A Convertible Preferred Stock and two Investor Warrants. Each Investor Warrant allows the holder to purchase one share of common stock, meaning each unit links to two potential common shares through its warrants, subject to warrant terms.
Under what regulatory framework is Daré Bioscience (DARE) conducting this offering?
Daré Bioscience is conducting the Investor Unit offering under a Regulation A program supported by an offering statement on Form 1-A. This statement, file number 024-12688, was most recently qualified by the SEC on April 1, 2026, with related offering circulars dated January 6 and March 26, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
